Association between Reflux Esophagitis Incidence and Palmar Hyperhidrosis

Chun-Gu Cheng1,2,3, Wu-Chien Chien4,5,6, Chia-Peng Yu6, Chi-Hsiang Chung5,6 and Chun-An Cheng7,*

1 Department of Emergency Medicine, Taoyuan Armed Forces General Hospital, National Defense Medical Center, Taoyuan 32549, Taiwan; doc50015@yahoo.com.tw
2 Department of Emergency and Critical Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan
3 Department of Emergency Medicine, Xin Tai General Hospital, New Taipei 24262, Taiwan
4 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 11490, Taiwan; chienwu@ndmctsgh.edu.tw
5 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; g694810042@gmail.com
6 School of Public Health, National Defense Medical Center, Taipei 11490, Taiwan; yu6641@gmail.com
7 Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan

* Correspondence: cca@ndmctsgh.edu.tw; Tel.: +886-2-87927173

Received: 23 May 2020; Accepted: 21 June 2020; Published: 23 June 2020

Abstract: The autonomic dysfunction in palmar hyperhidrosis (PH) includes not only sympathetic overactivity but also parasympathetic impairment. A decrease of parasympathetic tone has been noted in gastroesophageal reflux disease of neonates and adults. Patients with reflux esophagitis have a defective anti-reflux barrier. The association between reflux esophagitis and PH is deliberated in this article. The National Health Insurance Database in Taiwan was used. At first-time visits, PH patients were identified by the International Classification of Disease, 9th Revision, Clinical Modification disease code of 780.8 without endoscopic thoracic sympathectomy. Patients were matched by age and gender as control groups. The reflux esophagitis incidence was assessed using disease codes 530.11, 530.81, and 530.85. The factors related to reflux esophagitis were established by the Cox proportional regression model. The risk of reflux esophagitis in PH patients had a hazard ratio of 3.457 (95% confidence interval: 3.043–3.928) after adjustment of the other factors. We confirmed the association between reflux esophagitis and PH. Health care providers must be alerted to this relationship and other risk factors of reflux esophagitis to support suitable treatments to improve the quality of life of patients.

Keywords: parasympathetic withdrawal; reflux esophagitis; palmar hyperhidrosis

1. Introduction

Patients with palmar hyperhidrosis (PH) suffer from over-production of sweat in the palms induced by stress or exercise, which affects quality of life. A sympathetic overactivity of skin during stimulation by mental and thermal responses in PH patients has been shown [1]. The autonomic dysfunction in PH was found in a previous study to involve sympathetic overactivity combined with parasympathetic impairment [2]. The sympathetic overactivity in PH causes increased risk of cardiovascular disease and ischemic stroke compared with that of sympathectomy patients [3–5]. Given the parasympathetic disturbance present in both PH and reflux esophagitis, the relationship of two diseases was worthy of study.
Gastroesophageal reflux disease (GERD) is the backwash of gastric substances into the esophagus that causes symptoms with life-quality impairment [6,7]. The anti-reflux barrier is at the esophagogastric (EG) junction with the lower esophageal sphincter (LES) and curial diaphragm [8]. Past studies in neonates and adults showed that GERD events presented with decreased parasympathetic activity [9,10]. Disturbance of vagal activity could frequently relax the transient lower esophageal sphincter and reduce deglutition with delayed gastric empty [11]. The majority of GERD patients have no mucosal injury. Patients with reflux esophagitis, compared with non-erosive reflux, have anti-reflux mechanism impairment [12].

The relationship between reflux esophagitis and PH has not been discussed before. Both PH and reflux esophagitis include parasympathetic dysfunction; we designed a population-based retrospective cohort study to evaluate the possibility of an interaction between PH and sequent development of reflux esophagitis.

We assumed that increased sympathetic activity with parasympathetic impairment in PH patients may increase the incidence of long-term reflux esophagitis. We also checked other possible factors for health care providers, e.g., modifying lifestyle and adequate treatment, to reduce incidence.

2. Materials and Methods

2.1. Database

National health insurance in Taiwan started in 1995 and is run completely by the government. It includes approximately 99% of citizens in Taiwan. The longitudinal national health insurance research database (LNHIRD) contains one million randomly sampled patients and their records from 1999 onward. In LNHIRD, for personal privacy, data for each patient are encrypted with an original identification number. All outpatient and inpatient medical claims records in hospitals or clinics contain up to three outpatient disease codes and five inpatient disease codes according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). Our study assessed the occurrence of reflux esophagitis in PH patients by the LNHIRD from 1 January 2000 to 31 December 2013. Our study was approved by TSGHIRB-2-104-05-126.

2.2. Design

We found newly diagnosed PH cases (ICD-9-CM disease code 780.8) where endoscopic thoracic sympathectomies were not performed (operation code 05.29) from 1 January 2000 to 31 December 2013 in the LNHIRD of Taiwan. The disease code of PH were evaluated in previous studies [3,4]. The index date was assigned as the first visiting date for PH. Since reflux esophagitis includes an impairment of the anti-reflux barrier, compared with non-erosive esophagitis [12], we selected reflux esophagitis (ICD-9-CM disease codes 530.11, 530.81, and 530.85) as the outcome. The reflux esophagitis codes were assessed in a past study [13]. The second date was the diagnosis of reflux esophagitis in PH patients or the end time of study. We excluded (1) younger than 18 years old patients as they are often students in school preparing for entrance examinations with less time to seek out healthcare, (2) unidentified genders, and (3) PH and reflux esophagitis patients diagnosed before the study start date. The control group was designed by matching patients according to age, gender, and index date. The flow diagram of the study is presented in Figure 1.
The ICD-9-CM disease codes of comorbidities included hypertension (401–405), hyperlipidemia (272), obesity (278), diabetes mellitus (250), depression (296.2–296.3, 296.82, 330.4, 331), asthma (493), constipation (564.0), allergic rhinitis (477), obstructive sleep apnea (327.23, 780.51, 780.53, 780.57), osteoarthritis (715), osteoporosis (733), chronic obstructive pulmonary disease (491, 492, 494, 496), anxiety (300.1–300.3, 300.5–300.9), congestive heart failure (428), chronic kidney disease (580–589), and thyrotoxicosis (242).

2.3. Statistical Analysis

The categorical parameters were assessed by Chi-squared ($X^2$) test and the continuous parameters by Student t-test for descriptive statistics according to the PH and non-PH groups, the statistical significance was set at a $p$ value < 0.05. The relative factors of reflux esophagitis were assessed by Cox proportional regression with the hazard ratio (HR). The SPSS software version 21 (Asia Analytics Taiwan Ltd., Taipei, Taiwan) was employed for all analyses.

3. Results

The occurrence of reflux esophagitis was tracked for a mean of 10.03 follow-up years. The incidence of reflux esophagitis was significantly higher in the PH group at 1.34% (344/25,626) than the non-PH group at 1.23% (1263/102,504) (log-rank $p < 0.001$, Figure 2).
The cumulative incidence of reflux esophagitis was higher in the PH group compared to the control group during spring and summer and in those with lower incomes, living in middle Taiwan or a higher urban area, and visiting a medical center or regional hospital. However, fewer comorbid conditions were noted in PH patients (Table 1).

**Table 1.** The characteristics of the palmar hyperhidrosis and control groups.

| Variables                  | PH (%)       | Non-PH (%)    | p      |
|----------------------------|--------------|---------------|--------|
| Total                      | 25,626       | 102,504       |        |
| Gender (Male)              | 12,131 (47.34)| 48,524 (47.34)| 0.999  |
| Age (years)                | 28.16 ± 9.57 | 28.21 ± 9.79 | 0.999  |
| Catastrophic illness       | 88 (0.34)    | 5245 (5.12)   | <0.001 *|
| Insured premium ($USD)     |              |               |        |
| <600                       | 19,900 (77.66)| 76,864 (74.99)| <0.001 *|
| 600–1167                   | 3434 (13.4)  | 15,537 (15.16)|        |
| ≥1167                      | 2292 (8.94)  | 10,103 (9.86) |        |
| Hypertension               | 142 (0.55)   | 2456 (2.4)    | <0.001 *|
| Hyperlipidemia             | 29 (0.11)    | 1661 (1.62)   | <0.001 *|
| Obesity                    | 4 (0.02)     | 51 (0.05)     | 0.017 * |
| Diabetes mellitus          | 75 (0.29)    | 2648 (2.58)   | <0.001 *|
| Depression                 | 38 (0.15)    | 309 (0.3)     | <0.001 *|
| Asthma                     | 32 (0.12)    | 682 (0.67)    | <0.001 *|
Table 1. Cont.

| Variables                                | PH (%)       | Non-PH (%)    | \( p \)     |
|------------------------------------------|--------------|---------------|-------------|
| Constipation                             | 10 (0.04)    | 132 (0.13)    | <0.001 *    |
| Allergic rhinitis                        | 4 (0.02)     | 109 (0.11)    | <0.001 *    |
| Obstructive sleep apnea                  | 2 (0.01)     | 45 (0.04)     | <0.005 *    |
| Osteoarthritis                           | 3 (0.01)     | 381 (0.37)    | <0.001 *    |
| Osteoporosis                             | 0            | 84 (0.08)     | <0.001 *    |
| Chronic obstructive pulmonary disease    | 70 (0.27)    | 120 (1.17)    | <0.001 *    |
| Anxiety                                  | 35 (0.14)    | 305 (0.3)     | <0.001 *    |
| Congestive heart failure                 | 13 (0.05)    | 282 (0.28)    | <0.001 *    |
| Chronic kidney disease                   | 15 (0.06)    | 1094 (1.07)   | <0.001 *    |
| Thyrotoxicosis                           | 25 (0.1)     | 397 (0.39)    | <0.001 *    |

**Season**

- Spring (3–5): 7819 (30.51) vs. 26,354 (25.71)
- Summer (6–8): 8996 (35.1) vs. 25,633 (25.01)
- Autumn (9–11): 4531 (17.68) vs. 24,831 (24.22)
- Winter (12, January, February): 4280 (16.7) vs. 25,686 (25.06)

**Location**

- Northern: 9915 (38.69) vs. 42,264 (41.23)
- Middle: 8714 (34) vs. 28,514 (27.82)
- Southern: 6081 (23.73) vs. 25,825 (25.19)
- Eastern: 834 (3.25) vs. 5375 (5.24)
- Outlets islands: 82 (0.32) vs. 526 (0.51)

**Urbanization level**

- 1 (The highest): 8498 (33.16) vs. 37,100 (36.19)
- 2: 11,186 (43.65) vs. 41,349 (40.34)
- 3: 3783 (14.76) vs. 9194 (8.97)
- 4 (The lowest): 2159 (8.43) vs. 14,861 (14.5)

**Hospital levels**

- Medical center: 6896 (26.91) vs. 26,362 (25.72)
- Regional hospital: 10,729 (41.87) vs. 28,252 (27.56)
- Local hospital: 8001 (31.22) vs. 47,890 (46.72)

The risk factors of reflux esophagitis were higher in PH patients with a HR of 3.457 (95% confidence interval (CI): 3.043–3.928), male gender with a HR of 2.376 (95% CI: 2.129–2.651), hypertension (HR: 1.73 (95% CI: 1.161–2.864)), diabetes mellitus (HR: 1.479 (95% CI: 1.271–1.714)), depression (HR: 1.512 (95% CI: 1.112–2.005)), chronic obstructive pulmonary disease (HR: 1.842 (95% CI: 1.34–2.537)), anxiety (HR: 2.031 (95% CI: 1.301–3.172)), and chronic kidney disease (HR: 1.363 (95% CI: 1.039–1.788)) after adjustment for the age of study group, income, level of health care, and season. (Table 2).

Table 2. Risk factors of reflux esophagitis.

| Variables                                | Crude HR | 95% CI     | \( p \)   | Adjusted HR | 95% CI     | \( p \)   |
|------------------------------------------|----------|------------|-----------|-------------|------------|-----------|
| Palmar hyperhidrosis                     | 2.903    | 2.569–3.279| <0.001 *  | 3.457       | 3.043–3.928| <0.001 *  |
| Gender (Female)                          | Reference Reference |
| Male                                     | 2.167    | 1.454–2.667| <0.001 *  | 2.376       | 2.129–2.651| <0.001 *  |
| Age (years)                              | 1.002    | 0.948–1.068| 0.245     | 0.997       | 0.992–1.001| 0.161     |
| Catastrophic illness                     | 0.897    | 0.601–0.972| 0.008 *   | 0.814       | 0.704–0.901| 0.006 *   |
| Insured premium (USD)                    |          |            |           |             |            |           |
| <600                                     | Reference Reference |
| 600–1167                                 | 1.024    | 0.467–1.464| 0.802     | 0.959       | 0.672–1.368| 0.816     |
| ≥1167                                    | 1.805    | 0.225–2.401| 0.554     | 1.766       | 0.384–2.598| 0.453     |
Table 2. Cont.

| Variables                  | Crude HR | 95% CI     | p      | Adjusted HR | 95% CI     | p      |
|----------------------------|----------|------------|--------|-------------|------------|--------|
| Hypertension               | 1.567    | 1.005–2.842| <0.001*| 1.730       | 1.161–2.864| <0.001*|
| Hyperlipidemia             | 0.799    | 0.264–1.985| 0.465  | 0.972       | 0.486–1.597| 0.462  |
| Obesity                    | 2.297    | 0.446–5.012| 0.246  | 2.208       | 0.985–4.95 | 0.154  |
| Diabetes mellitus          | 1.454    | 1.121–1.77 | 0.001* | 1.479       | 1.272–1.714| <0.001*|
| Depression                 | 1.498    | 1.064–1.932| 0.007* | 1.512       | 1.112–2.005| <0.001*|
| Asthma                     | 0.952    | 0.454–1.701| 0.465  | 0.880       | 0.555–1.396| 0.588  |
| Constipation               | 0.882    | 0.498–1.985| 0.703  | 0.934       | 0.67–1.588 | 0.879  |
| Allergic rhinitis          | 0.468    | 0.105–2.345| 0.154  | 0.537       | 0.119–2.888| 0.101  |
| Obstructive sleep apnea    | 9.565    | 0.099–78.452| 0.875 | 11.245      | 0.167–197.752| 0.786|
| Osteoarthritis             | 2.085    | 0.498–7.017| 0.452  | 1.974       | 0.626–6.054| 0.297  |
| Chronic obstructive        | 1.442    | 1.154–2.448| 0.003* | 1.842       | 1.34–2.537 | <0.001*|
| pulmonary disease          | 2.989    | 1.498–3.902| <0.001*| 2.031       | 1.301–3.172| <0.001*|
| Congestive heart failure   | 1.454    | 0.598–3.012| 0.678  | 1.795       | 0.798–2.454| 0.295  |
| Chronic kidney disease     | 1.227    | 1.005–1.704| 0.041* | 1.363       | 1.039–1.788| 0.025* |
| Thryrotoxicosis            | 0.996    | 0.124–1.642| 0.564  | 1.088       | 0.157–1.516| 0.215  |

| Season                     | Crude HR | 95% CI     | p      | Adjusted HR | 95% CI     | p      |
|----------------------------|----------|------------|--------|-------------|------------|--------|
| Spring                     | 1.452    | 0.742–1.897| 0.872  | 1.045       | 0.597–1.787| 0.842  |
| Summer                     | 0.804    | 0.512–0.911| 0.002* | 0.779       | 0.678–0.893| 0.003* |
| Autumn                     | 0.667    | 0.334–0.876| 0.004* | 0.564       | 0.467–0.642| 0.001* |
| Winter                     | 0.795    | 0.642      | 0.053  | 0.889       | 0.743–1.063| 0.197  |
| Urbanization level         |          |            |        |             |            |        |
| 1 (The highest)            | 0.701    | 0.611      | 0.025* | 0.861       | 0.754–0.984| 0.028* |
| 2                         | 0.685    | 0.572      | 0.001* | 0.676       | 0.575–0.796| <0.001*|
| 3                         |          |            |        |             |            |        |
| 4 (The lowest)             | Reference| Reference  |        | Reference   | Reference  |        |
| Hospital levels            |          |            |        |             |            |        |
| Hospital center            | 1.756    | 0.425–2.905| 0.498  | 1.295       | 0.498–1.795| 0.540  |
| Regional hospital          | 1.015    | 0.373–1.785| 0.811  | 0.884       | 0.331–1.454| 0.735  |
| Local hospital             | Reference| Reference  |        | Reference   | Reference  |        |

* p < 0.05. CI: confidence interval; HR: hazards ratio.

4. Discussion

To our knowledge, this is the first investigation about the sequent risk of reflux esophagitis in PH patients. The PH patients carried a higher risk of reflux esophagitis. The strength of our study is the population-based survey, which provided a large-sized sample of subjects and enabled us to assess the association between PH and reflux esophagitis. PH patients have excessive sweating in their palms due to a sympathovagal imbalance with high sympathetic activity and low parasympathetic function [2]. The potential mechanism of reflux esophagitis is through decreasing esophageal motility and delayed gastric emptying, increasing lower esophageal sphincter relaxation following reflux esophagitis incidents.

The prevalence of reflux esophagitis in hospital-based studies is 12–17.3% in Taiwan, and the majority of patients present with a mild degree and are free of reflux symptoms [14,15]. Certain epidemiologic factors, such as longevity, obesity, Helibacter pylori, and use of medications such as antihistamines, calcium channel blockers, anticholinergic agents, etc., are conducive to lower esophageal sphincter relaxation, and explain the increased prevalence of GERD [12]. However, other patients do not appear to have common factors, so discovery of another possible factor is important.

Peristalsis of the gastrointestinal tract is controlled by a parasympathetic nerve, and it enhances esophageal stomach motility with gastric emptying, and a sympathetic nerve inhibits esophageal contraction. The LES maintains tonic contractions of smooth muscles through neurogenic factors. The LES pressure is reduced by splanchnic sympathetic nerve stimulation and vagal-mediated tonic contractions [1]. A significant decrease of parasympathetic activity was noted during the prior reflux period in a neonate study [9]. More than 60% of GERD patients had transient lower esophageal sphincter relaxation (TLESR) [16]. One study found a higher frequency of TLESR and lower LES pressure in GERD patients compared with that of control in humans [17]. LES function is regulated by...
the enteric nervous system, with mechanoreceptors sensitization through the vagus nerve afferents from the stomach, signals then transfer into the nucleus tractus solitaries, whereas the caudal to the obex of dorsal motor nucleus of the vagus complex travel to vagal efferent fibers of the LES, resulting in relaxation.

GERD is multifactorial with a lack of balance between the aggressiveness of the refluxate into the esophagus and the failure of protective motility mechanisms or a defective valvular structure mechanism at the level of the EG junction [18,19]. It can impair vagal nerve responses by distal esophagus injury, particularly the afferent sensitization [20]. The anti-reflux barrier is localized at the EG junction and maintained by intrinsic LES pressure; the crural diaphragm is extrinsically compressed by the LES. Hiatal hernias reduce the barrier effect of the EG junction because the stomach is displaced proximally through the separation of the above two structures. The anti-reflux barrier is impaired in reflux esophagitis [12].

Comorbidities could assist health care providers in identifying better therapeutic approaches. Reflux esophagitis in PH patients occurred more frequently in spring–summer with possible over-sweating and sympathetic overactivity following higher air temperatures, higher urbanization areas, and higher care for their health conditions. Hypertension is the most common comorbidity in GERD [21], and our study discovered hypertension increased by a 1.7-fold the risk of reflux esophagitis. The male sex showed as a risk factor for reflux esophagitis in a past study [22]. The risk factors for Chinese reflux esophagitis were hiatal hernia (odds ratio (OR):12.2), male sex (OR = 4.2), and chronic obstructive pulmonary disease (OR = 3.4) [9]. Chronic obstructive pulmonary disease caused negative pressure of the intrathoracic space, airway obstruction inducing TLESR, with anti-cholinergic medications reducing LES pressure [23]. Our study found male gender and chronic obstructive pulmonary disease carried 2.4- and 1.8-fold risks, respectively, of developing reflux esophagitis. One meta-analysis found greater risk (OR: 1.61) of GERD in diabetes mellitus patients compared with that of non-diabetes mellitus patients [24]. This study showed a similar result in that diabetes mellitus increased the risk of reflux esophagitis. Reflux esophagitis is also associated with anxiety, depression, and gastrointestinal symptoms [25]. The brain magnetic resonance images by esophageal stimulation presented higher activity of anterior insula and dorsal anterior cingulate gyri in negative mood patients than neutral patients [26]. Depression may induce reflux symptoms by decreasing the LES pressure, reducing the motility of the esophagus, increasing gastric acid secretions, or postponing the esophageal clearance of acid by the various stressors. Patients with major depression had an increased rate for GERD with an OR of 3.16 [13]. Our study found anxiety and depression increased by 2- and 1.5-fold, respectively, the risk of reflux esophagitis, which is lower than the previous study, possibly due to a different study design with PH and non-PH patients and a lower prevalence of around 40% of reflux esophagitis in GERD [12]. In Japan, 44.0% of patients with chronic kidney disease also have GERD [27]; our study found a 1.4-fold risk in chronic kidney disease with reflux esophagitis.

More GERD patients with comorbidities were elderly. Depression, asthma, and obesity were more common in middle-aged GERD patients. Allergic rhinitis was more common in young-aged GERD patients [21]. GERD incidence increased in in subjects over 40 years of age [28]. PH incidence decreased in older patients [29]. PH patients seek healthcare at a younger age, while a similar trend is not noticed with GERD. PH patients in our study had a mean age of 28 years with less osteoarthritis and osteoporosis. Previous studies observed that obesity with sympathetic overactivity and vagal withdrawal increased the risk of GERD; the autonomic impairment improved after weight reduction [30,31]. In contrast, our study did not find obesity increased the risk of reflux esophagitis, with a lower prevalence of obesity in youth of Asian ethnicity. Past studies showed that patients with asthma and sleep apnea had peristaltic dysfunction and increased risk of GERD [32,33], but our study did not find that asthma increased the risk of GERD, with lower prevalence in the young-aged group. Thoracoscopic sympathectomy decreases sympathetic activity and revises parasympathetic activity with a possible cardiac protection effect [34]. However, a past study found sympathectomy did not influence TLESR in animals [35]. We also surveyed PH after endoscopic thoracic sympathectomy and
noted a similar result; no reduction in reflux esophagitis occurrence in humans. The potential reason may be the reduced cardiac sympathetic activity, such as a beta blocker effect, that did not affect TLESR of the EG junction without a reflux esophagitis preventive benefit with inadequate vagal stimulation after endoscopic thoracic sympathectomy. In addition, improved symptoms and parasympathetic activity in GERD were seen after proton pump inhibitor (PPI) treatment in a past study [36]. Future study is needed to evaluate the effect of PPI in PH patients. Reflux esophagitis can change to esophageal adenocarcinoma, but in our study only three patients with esophageal carcinoma (ICD9-CM: 150) were in the PH group and nine patients with esophageal carcinoma were in non-PH group, with statistical insignificant ($p = 0.665$).

There were some limitations in our study. First, because we detected reflux esophagitis by disease codes, the lack of endoscopy reports meant information on severity was unavailable. Further studies could collect endoscopy data to confirm the relationship between PH and different degrees of esophagitis. There was a lower prevalence of the two diseases in young adults according to seeking healthcare in the claim dataset; a registration study can improve this problem. Second, male sex, smoking habits, obesity, and hiatus hernia history carried risks of GERD development in a past study [10]. The information of patients such as body mass index, laboratory tests, and drinking and smoking history were unavailable in the dataset, which may lead to an overestimation of the reflux esophagitis risk of PH. Third, over-sweating caused young adults in Taiwan to seek healthcare help. Our study focused on Chinese ethnicity; the generalizability to other ethnic groups needs study in the future.

5. Conclusions

Our findings indicate that clinicians should understand the increased risk of reflux esophagitis for PH patients. GERD, which is a very common neurogastroenterologic problem, may be induced in PH patients due to autonomic dysregulation. In clinical practice, the patients with PH complained about annoying symptoms of GERD and considered consulting a gastroenterologist for treatment. In severer GERD cases with reflux esophagitis, the duration of PPI therapy may improve the underlying autonomic imbalance.

Author Contributions: Data curation, W.-C.C. and C.-A.C.; Formal analysis, W.-C.C. and C.-H.C.; Investigation, C.-G.C. and C.-A.C.; Methodology, W.-C.C.; Project administration, W.-C.C.; Resources, W.-C.C.; Software, W.-C.C.; Supervision, C.-A.C.; Validation, C.-A.C.; Visualization, C.-P.Y.; Writing—original draft, C.-G.C.; Writing—review and editing, C.-A.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Iwase, S.; Ikeda, T.; Kitazawa, H.; Hakusui, S.; Sugeno, J.; Mano, T. Altered response in cutaneous sympathetic outflow to mental and thermal stimuli in primary palmoplantar hyperhidrosis. J. Auton. Nerv. Syst. 1997, 64, 65–73. [CrossRef]
2. Birner, P.; Heinzl, H.; Schindl, M.; Pumprla, J.; Schneider, P. Cardiac autonomic function in patients suffering from primary focal hyperhidrosis. Eur. Neurol. 2000, 44, 112–116. [CrossRef] [PubMed]
3. Cheng, C.G.; Cheng, C.A.; Chien, W.C.; Chung, C.H.; Lee, J.T. Associated With Ischemic Stroke Risk Reduction After Endoscopic Thoracic Sympathectomy for Palmar Sweating. J. Stroke Cerebrovasc. Dis. 2018, 27, 2235–2242. [CrossRef] [PubMed]
4. Cheng, C.A.; Cheng, C.G.; Chu, H.; Lin, H.C.; Chung, C.H.; Chiu, H.W.; Chien, W.C. Risk Reduction of Long-Term Major Adverse Cardiovascular Events After Endoscopic Thoracic Sympathectomy in Palmar Hyperhidrosis. Clin. Auton. Res. 2017, 27, 393–400. [CrossRef] [PubMed]
5. Park, J.M.; Moon, D.H.; Lee, H.S.; Park, J.Y.; Lee, J.W.; Lee, S. Hyperhidrosis, Endoscopic Thoracic Sympathectomy, and Cardiovascular Outcomes: A Cohort Study Based on the Korean Health Insurance Review and Assessment Service Database. Int. J. Environ. Res. Public Health 2019, 16, 3925. [CrossRef]
6. Madisch, A.; Kulich, K.; Malferttheiner, P.; Ziegler, K.; Bayerdörffer, E.; Miehlke, S.; Labenz, J.; Carlsson, J.; Wiklund, I. Impact of reflux disease on general and disease-related quality of life—evidence from a recent comparative methodological study in Germany. Z. Gastroenterol. 2003, 41, 1137–1143. [CrossRef]
7. De Souza Cury, M.; Ferrari, A.; Ciconelli, R.; Ferraz, M.; Moraes-Filho, J.P.P. Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. Dis. Esophagus 2006, 19, 289–293. [CrossRef]
8. Weinberg, D.S.; Kadish, S.L. The diagnosis and management of gastroesophageal reflux disease. Med. Clin. N. Am. 1996, 80, 411–429. [CrossRef]
9. Djeddi, D.-D.; Kongolo, G.; Stéphan-Blanchard, E.; Ammari, M.; Léké, A.; Delanaud, S.; Bach, V.; Telliez, F. Involvement of autonomic nervous activity changes in gastroesophageal reflux in neonates during sleep and wakefulness. PLoS ONE 2013, 8, e83464. [CrossRef]
10. Milovanovic, B.; Filipovic, B.; Mutavdzin, S.; Zdravkovic, M.; Gligorijevic, T.; Paunovic, J.; Arsic, M. Cardiac autonomic dysfunction in patients with gastroesophageal reflux disease. World J. Gastroenterol. 2015, 21, 6982. [CrossRef]
11. Mittal, R.K.; Holloway, R.; Dent, J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology 1995, 109, 1547–1554. [CrossRef]
12. Nordenstedt, H.; Lagergren, J. Environmental Factors in the Etiology of Gastroesophageal Reflux Disease. Expert Rev. Gastroenterol. Hepatol. 2008, 2, 93–103. [CrossRef] [PubMed]
13. Chou, P.-H.; Lin, C.-C.; Lin, C.-H.; Tsai, C.-J.; Cheng, C.; Chuo, Y.-P.; Chan, C.-H.; Lan, T.-H. Prevalence of gastroesophageal reflux disease in major depressive disorder: A population-based study. Psychosomatics 2014, 55, 155–162. [CrossRef]
14. Chen, T.-S.; Chang, F.-Y. The prevalence and risk factors of reflux esophagitis among adult Chinese population in Taiwan. J. Clin. Gastroenterol. 2007, 41, 819–822. [CrossRef]
15. Ou, J.-L.; Tu, C.-C.; Hsu, P.-I.; Pan, M.-H.; Lee, C.-C.; Tsay, F.-W.; Wang, H.-M.; Cheng, L.-C.; Lai, K.-H.; Yu, H.-C. Prevalence and risk factors of erosive esophagitis in Taiwan. J. Clin. Med. Assoc. 2012, 75, 60–64. [CrossRef] [PubMed]
16. Dodds, W.J.; Dent, J.; Hogan, W.J.; Helm, J.F.; Hauser, R.; Patel, G.K.; Egide, M.S. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N. Engl. J. Med. 1982, 307, 1547–1552. [CrossRef] [PubMed]
17. Schneider, J.H.; Küper, M.A.; Königsrainer, A.; Brücher, B.L. Transient lower esophageal sphincter relaxation and esophageal motor response. J. Surg. Res. 2010, 159, 714–719. [CrossRef] [PubMed]
18. Boeckxstaens, G.E.; Rohof, W.O. Pathophysiology of gastroesophageal reflux disease. Gastroenterol. Clin. N. Am. 2014, 43, 15–25. [CrossRef]
19. Gyawali, C.; Roman, S.; Bredenoord, A.; Fox, M.; Keller, J.; Pandolfino, J.; Sifrim, D.; Tatum, R.; Yadlapati, R.; Savarino, E. Classification of esophageal motor findings in gastro-esophageal reflux disease: Conclusions from an international consensus group. Neurogastroenterol. Motil. 2017. [CrossRef] [PubMed]
20. Shaker, R. Gastroesophageal reflux disease: Beyond mucosal injury. J. Clin. Gastroenterol. 2007, 41, S160–S162. [CrossRef]
21. Moraes-Filho, J.P.P.; Navarro-Rodriguez, T.; Eisig, J.N.; Barbuti, R.C.; Chinzon, D.; Quigley, E.M. Comorbidities are frequent in patients with gastroesophageal reflux disease in a tertiary health care hospital. Clinics 2009, 64, 785–790. [CrossRef]
22. Du, J.; Liu, J.; Zhang, H.; Yu, C.-H.; Li, Y.-M. Risk factors for gastroesophageal reflux disease, reflux esophagitis and non-erosive reflux disease among Chinese patients undergoing upper gastrointestinal endoscopic examination. World J. Gastroenterol. 2007, 13, 6009. [CrossRef] [PubMed]
23. Lee, A.L.; Goldstein, R.S. Gastroesophageal reflux disease in COPD: Links and risks. Int. J. Chron. Obstruct. Pulmon. Dis. 2015, 10, 1935. [CrossRef] [PubMed]
24. Sun, X.-M.; Tan, J.-C.; Zhu, Y.; Lin, L. Association between diabetes mellitus and gastroesophageal reflux disease: A meta-analysis. World J. Gastroenterol. 2015, 21, 3085. [CrossRef]
25. Haug, T.T.; Myklesten, A.; Dahl, A. Are anxiety and depression related to gastrointestinal symptoms in the general population? Scand. J. Gastroenterol. 2002, 37, 294–298. [CrossRef] [PubMed]
26. Phillips, M.L.; Gregory, L.J.; Cullen, S.; Cohen, S.; Ng, V.; Andrew, C.; Giampietro, V.; Bullmore, E.; Zelaya, F.; Amaro, E. The effect of negative emotional context on neural and behavioural responses to oesophageal stimulation. Brain 2003, 126, 669–684. [CrossRef]
27. Kawaguchi, Y.; Mine, T.; Kawana, I.; Yasuzaki, H.; Kokuho, T.; Toya, Y.; Ohnishi, T.; Umemura, S. Gastroesophageal reflux disease in chronic renal failure patients: Evaluation by endoscopic examination. *Tokai J. Exp. Clin. Med.* **2009**, *34*, 80–83. [PubMed]

28. Lien, H.-C.; Chang, C.-S.; Yeh, H.-Z.; Ko, C.-W.; Chang, H.-Y.; Cheng, K.; Sung, F.-C. Increasing prevalence of erosive esophagitis among Taiwanese aged 40 years and above: A comparison between two time periods. *J. Clin. Gastroenterol.* **2009**, *43*, 926–932. [CrossRef] [PubMed]

29. Chu, D.; Chen, R.-C.; Lee, C.-H.; Yang, N.-P.; Chou, P. Incidence and frequency of endoscopic sympathectomy for the treatment of hyperhidrosis palmaris in Taiwan. *Kaohsiung J. Med. Sci.* **2010**, *26*, 123–129. [CrossRef]

30. El-Serag, H.B.; Graham, D.Y.; Satia, J.A.; Rabeneck, L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. *Am. J. Gastroenterol.* **2005**, *100*, 1243–1250. [CrossRef]

31. Karason, K.; Mølgaard, H.; Wikstrand, J.; Sjöström, L. Heart rate variability in obesity and the effect of weight loss. *Am. J. Cardiol.* **1999**, *83*, 1242–1247. [CrossRef]

32. Amarasiri, D.L.; Pathmeswaran, A.; de Silva, H.J.; Ranasingha, C.D. Response of the airways and autonomic nervous system to acid perfusion of the esophagus in patients with asthma: A laboratory study. *BMC Pulm. Med.* **2013**, *13*, 33. [CrossRef] [PubMed]

33. Kuribayashi, S.; Kusano, M.; Kawamura, O.; Shimoyama, Y.; Maeda, M.; Hisada, T.; Ishizuka, T.; Dobashi, K.; Mori, M. Mechanism of gastroesophageal reflux in patients with obstructive sleep apnea syndrome. *Neurogastroenterol. Motil.* **2010**, *22*, 611. [CrossRef] [PubMed]

34. Bygstad, E.; Terkelsen, A.J.; Pilegaard, H.K.; Hansen, J.; Mølgaard, H.; Hjortdal, V.E. Thoracoscopic sympathectomy increases efferent cardiac vagal activity and baroreceptor sensitivity. *Eur. J. Cardio-Thorac Surg.* **2013**, *44*, e193–e199. [CrossRef] [PubMed]

35. Staunton, E.; Smid, S.D.; Dent, J.; Blackshaw, L.A. Triggering of transient LES relaxations in ferrets: Role of sympathetic pathways and effects of baclofen. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2000**, *279*, G157–G162. [CrossRef] [PubMed]

36. Jones, E.; Perring, S.; Khattab, A.; Allenby-Smith, O. The effects of proton pump inhibitors on autonomic tone in patients with erosive and non-erosive esophagitis. *Neurogastroenterol. Motil.* **2016**, *28*, 659–664. [CrossRef]